Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HFB3024
- Development stage
- Preclinical
- Lead developer
- HiFiBiO Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
HFB3024 (also known as HFB302401) is a biparatopic antibody depletor developed by HiFiBiO Therapeutics, targeting Killer cell Lectin-like Receptor G1 (KLRG1). It is designed to selectively deplete KLRG1-positive cells, which are implicated in the pathogenesis of various autoimmune and inflammatory diseases. Developed using the proprietary Drug Intelligence Science (DIS®) platform, which integrates single-cell analysis with AI/ML, HFB3024 aims to provide a best-in-class therapeutic option by utilizing a biparatopic binding strategy to enhance the depletion of target cells. The program is currently in the discovery and preclinical stages of development for immunology and inflammation (I&I) indications.
- Other names
- KLRG1 biparatopic depletorKLRG-1 biparatopic depletorKLRG 1 biparatopic depletor
02
Targets
MAFA (V-maf musculoaponeurotic fibrosarcoma oncogene homolog A)
Beyond the preview
Go deeper on HFB3024.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HFB3024.